Paul has over 20 years of clinical development experience having worked at GlaxoSmithKline, Johnson & Johnson and Novartis. In his current role as Head of Rare Disease Clinical Development at Roche Pharma Research and Early Development (pRED), he leads a group which provides dedicated and expert leadership to the design, implementation and execution of rare disease development programs. They support the Roche collective mission to deliver medicines with transformative therapeutic impact to patients with rare disorders through clinical trial innovation and smart operational execution.